Septerna, Inc. - נכסים נקיים למניה בודדת SEPN

Septerna Inc (SEPN) specializes in developing GPCR receptor drugs, facing challenges such as a lack of profitability and dependence on external capital. Business growth relies on successes in treating endocrine pathologies and a strong scientific team, with the current figure standing at 8.42. The historical price action is presented below, complementing data on the flawless operation of robotic laboratories and the stable functioning of R&D centers.

Book value per share determines the portion of equity attributable to a single security upon the liquidation of all liabilities. By analyzing the trend in book value per share, an investor assesses the issuer's actual tangible asset base. The metric is calculated as the difference between assets and liabilities divided by the number of shares. For Septerna Inc (SEPN), this metric reflects the volume of investment in early-stage drug development. Capital growth here confirms the capitalization of intellectual property within the endocrinology sector.